Dr. John Powderly, M.D.
Claim this profileCarolina BioOncology Institute
About John Powderly, M.D.
Education:
- Received MD (Doctor of Medicine) from the University of Tennessee in 2006.
Experience:
- Founder and President of Carolina BioOncology Institute, also serving as an Oncologist.
- Focuses on Phase I immunotherapy clinical trials and cancer research.
- Manages on-site clinical laboratory services, including hematology and immunology.
- Specializes in translational tumor immunology research.
Area of expertise
Solid Tumors
John Powderly, M.D. has run 25 trials for Solid Tumors. Some of their research focus areas include:
Lung Cancer
John Powderly, M.D. has run 13 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Carolina BioOncology Institute
Carolina Bio Oncology
Clinical Trials John Powderly, M.D. is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting
1 award
Phase 1
10 criteria
TRE-515
for Cancer
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than normal cells to perturbations in nucleotide metabolism by DNA-targeting treatments such as TRE-515. The Primary objective is to determine the safety and maximum tolerability of TRE-515 when administered orally once daily as a single agent. The secondary objectives are to establish a recommended phase 2 dose (RP2D), to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of TRE-515, preliminary evaluation of antitumor activity, and to determine the effect of an acid reducing agent (ARA) on TRE-515 exposure. The exploratory objectives are to evaluate the relationship between TRE-515 exposure and plasma deoxynucleoside concentrations, evaluate the relationship between TRE-515 exposure and reductions in intracellular dCK on-target knockdown as measured by a \[18F\]-clofarabine (CFA) positron emission tomography (PET) probe, to evaluate the relationship between TRE-515 treatment and dCK and CDA gene expression in archived tumor tissue when available, to evaluate the relationship between tumor CDA and plasma deoxynucleoside (dC and dU) concentrations, and to explore the effect of TRE-515 treatment on gene expression in white blood cell populations.
Recruiting
1 award
Phase 1
3 criteria
More about John Powderly, M.D.
Clinical Trial Related
3 years of experience running clinical trials · Led 39 trials as a Principal Investigator · 12 Active Clinical Trials
Treatments John Powderly, M.D. has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Toripalimab
- Cetuximab
- MBRC-101
Breakdown of trials John Powderly, M.D. has run
Solid Tumors
Lung Cancer
Pancreatic Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Powderly, M.D. specialize in?
John Powderly, M.D. focuses on Solid Tumors and Lung Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is John Powderly, M.D. currently recruiting for clinical trials?
Yes, John Powderly, M.D. is currently recruiting for 12 clinical trials in Huntersville North Carolina. If you're interested in participating, you should apply.
Are there any treatments that John Powderly, M.D. has studied deeply?
Yes, John Powderly, M.D. has studied treatments such as Pembrolizumab, Nivolumab, Docetaxel.
What is the best way to schedule an appointment with John Powderly, M.D.?
Apply for one of the trials that John Powderly, M.D. is conducting.
What is the office address of John Powderly, M.D.?
The office of John Powderly, M.D. is located at: Carolina BioOncology Institute, Huntersville, North Carolina 28078 United States. This is the address for their practice at the Carolina BioOncology Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.